The Center for Disease Control and Prevention has released guidelines for COVID-19 Antibody testing in clinical and public health settings, highlighting the development of serological methods that will have important public and clinical health uses to monitor and respond to the COVID-19 pandemic.
- Serologic assays for SARS-CoV-2 now have Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA), which has independently reviewed their performance.
- Currently, there is no identified advantage of assays whether they test for IgG, IgM and IgG, or total antibody.
- It is important to minimize false positive test results by choosing an assay with high specificity and by testing populations and individuals with an elevated likelihood of previous exposure to SARS-CoV-2.
- Antibodies most commonly become detectable 1-3 weeks after symptom onset, at which time evidence suggests that infectiousness likely is greatly decreased and that some degree of immunity from future infection has developed. However, additional data are needed before modifying public health recommendations based on serologic test results, including decisions on discontinuing physical distancing and using personal protective equipment.
Read the guidelines Here.